Table 1 Clinical characteristics of infection patients caused by XDR-hvPA and XDR-non-hvPA

Age (years)

 ≤ 18

2 (4.3%)

5 (16.7%)

0.150

 19–59

11 (23.4%)

13 (43.3%)

0.066

 ≥ 60

34 (72.3%)

12 (40.0%)

0.005

Male

35 (74.5%)

26 (86.7%)

0.198

Hospital stay (< 30 days)

29 (61.7%)

23 (76.7%)

0.171

ICU^a admission

19 (40.4%)

12 (40.0%)

0.970

Underlying diseases

Chronic lung disease

23 (48.9%)

19 (63.3%)

0.216

Diabetes mellitus

9 (19.1%)

4 (13.3%)

0.506

Hypertension

17 (36.2%)

9 (30.0%)

0.577

Hyperlipidemia

4 (8.5%)

0 (0)

0.265

Invasive procedure

Gastric tube

42 (89.4%)

25 (83.3%)

0.675

PICC^b

33 (70.2%)

15 (50.0%)

0.074

Urinary catheter

31 (66.0%)

19 (63.3%)

0.814

Other

19 (40.4%)

10 (33.3%)

0.531

Previous antibiotic exposure

Carbapenems

14 (29.8%)

11 (36.7%)

0.530

Quinolones

9 (19.1%)

10 (33.3%)

0.159

Aminoglycosides

8 (17.0%)

2 (6.7%)

0.332

β-enzyme inhibitor

28 (59.6%)

16 (53.3%)

0.589

Polymyxin B

4 (8.5%)

2 (6.7%)

1.000

Cephalosporin

6 (12.8%)

5 (16.7%)

0.886